13 active not recruiting, 3 recruiting, 1 completed, 1 not yet recruiting. 18 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Active not recruiting 13, Recruiting 3, Completed 1, Not yet recruiting 1 |
| Phase 2 | 3 | Active not recruiting 2, Not yet recruiting 1 |
Follow Ruxience: new trials by email Literature Review of Ruxience trials Research Report on Ruxience
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial Biospecimen Collection, Computed Tomography, Cyclophosphamide - Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 102 | 2026-08-04 | 2026-10-13 |
| Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma Biospecimen Collection, Computed Tomography, Mosunetuzumab - Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features | Phase 3 | Recruiting | National Cancer Institute (NCI) | 600 | 2024-10-23 | 2026-10-29 |
| Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS Rituximab - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Recruiting | Amsterdam UMC, location VUmc | 200 | 2023-04-01 | 2023-04-28 |
| A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) Nemtabrutinib, Fludarabine, Cyclophosphamide - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 300 | 2023-03-16 | 2026-03-16 |
| Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Aspiration, Busulfan - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 66 | 2023-03-15 | 2026-07-30 |
| Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse Rituximab, Placebo - Polymyalgia Rheumatica | Phase 3 | Active not recruiting | Sint Maartenskliniek | 174 | 2023-02-09 | 2026-02-04 |
| Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed Rituximab, Placebo - Polymyalgia Rheumatica | Phase 3 | Completed | Sint Maartenskliniek | 114 | 2023-02-01 | 2026-02-03 |
| A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma Zanubrutinib, Rituximab, Lenalidomide - Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma | Phase 3 | Active not recruiting | BeOne Medicines | 799 | 2022-03-10 | 2026-10-15 |
| Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Primary Mediastinal Large B-Cell Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 244 | 2021-10-05 | 2026-10-01 |
| A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Pirtobrutinib, Bendamustine, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | Loxo Oncology, Inc. | 282 | 2021-09-23 | 2026-09-25 |
| A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Pirtobrutinib, Venetoclax, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | Loxo Oncology, Inc. | 600 | 2021-09-20 | 2026-01-29 |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 422 | 2021-05-20 | 2026-10-27 |
| Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 363 | 2019-10-22 | 2026-10-26 |
| Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate - Mantle Cell Lymphoma | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 689 | 2017-11-27 | 2026-09-14 |
| Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Blinatumomab - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 488 | 2014-05-19 | 2026-09-21 |
| Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Cyclophosphamide, Fludarabine Phosphate, Ibrutinib - Anemia, Chronic Lymphocytic Leukemia | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 529 | 2014-03-10 | 2026-08-28 |
| Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Bendamustine Hydrochloride, Biospecimen Collection, Bone Marrow Aspiration - Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 547 | 2014-01-15 | 2026-10-22 |
Leukemia, Lymphocytic, Chronic, B-Cell (5) · Burkitt Lymphoma (2) · Hematologic Diseases (2) · Lymphoma, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Non-Hodgkin (2) · Polymyalgia Rheumatica (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia (1) · Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myeloid, Acute (1)
National Cancer Institute (NCI) (8) · Loxo Oncology, Inc. (2) · Sint Maartenskliniek (2) · Amsterdam UMC, location VUmc (1) · BeOne Medicines (1) · Children's Oncology Group (1) · ECOG-ACRIN Cancer Research Group (1) · Merck Sharp & Dohme LLC (1) · SWOG Cancer Research Network (1)
United States (14) · Australia (6) · Canada (6) · China (4) · Poland (4) · Brazil (3) · Bulgaria (3) · Czechia (3) · France (3) · Hungary (3) · Israel (3) · Italy (3) · Japan (3) · Netherlands (3) · Puerto Rico (3)
Aatke van der Maas (1) · Aatke van der Maas, MD PhD (1) · Bob van Oosten, Dr (1) · Elizabeth A Brem (1) · Heather J Symons (1) · Jennifer A Woyach (1) · Jeremy S Abramson (1) · Kristie A Blum (1) · Lisa G Roth (1) · Mark R Litzow (1) · Mazyar Shadman (1) · Nilanjan Ghosh (1)
PMID 39400109, PMID 30501481, PMID 31365801, PMID 32589970, PMID 33288485, PMID 33439748, PMID 34274940, PMID 34634256, PMID 34686472, PMID 34865212, PMID 35427411, PMID 36485104, PMID 37801678, PMID 38215395, PMID 39047240, PMID 41363770, PMID 41363773, PMID 41749915, PMID 42425121, PMID 42660130, PMID 42832396
U10CA180820 (3), U10CA180821 (3), U10CA180888 (3), U10CA021115 (2), U10CA180886 (2), U24CA196172 (2), K23CA178183 (1), R01CA183444 (1), R01CA193541 (1), U10CA031946 (1)